In addition to intravenous (IV), MHC recently added a subcutaneous (SQ) administration route for Monoclonal Antibody (mAb) therapy.
Given the significant resources required for IV administration at outpatient COVID-19 mAbs, MHC mAb clinics are utilizing SQ REGEN-COV COVID-19 mAb more frequently for the treatment of patients with mild to moderate COVID-19. Although there are limited outcomes data, preliminary pharmacokinetic data suggests similar outcomes for SQ administration when compared to the IV route. The FDA EUA continues to recommend IV therapy over SQ route, except when IV infusion resources are limited such as in our current situation due to the rapid increase in demand of COVID-19 mAbs.
Adding SQ mAb therapy has allowed MHC to treat nearly 100 additional patients in the last few weeks since we added this treatment route. Patients have reported no more adverse reactions to the SQ route compared to the IV route. Both have been well tolerated. MHC’s mAb therapy team has treated over 1,800 COVID-19 positive patients to date.